Internal Medicine, Endocrinology, Diabetes, & Metabolism · Marrero, LA
NPI
1437160959
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
1111 Medical Center Blvd, Suite S 113
Marrero, LA, 70072
Phone (504) 349-6520
Groups this clinician bills Medicare through
Medicare paid, 2024
$63K
647 services
Medicare patients, 2024
228
Average age 74
Drug cost, 2024
$2.6M
6,149 prescriptions
Company payments, 2025
$7,850
From 19 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Tilak K Mallik was code 99215 (office e&m - established), 451 times for 211 patients. In total Tilak K Mallik billed 647 services in 12 codes, and Medicare paid $63K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-03-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 451 | 211 | $115.30 | $52K |
| 95251 Test - Miscellaneous | Office | 78 | 32 | $21.74 | $1,696 |
| 76536 Ultrasound - Nonspecific | Office | 33 | 31 | $66.47 | $2,193 |
| 99214 Office E&M - Established | Office | 28 | 24 | $92.72 | $2,596 |
| 99491 Chronic, Principal, and Transitional Care Management | Office | 17 | 11 | $57.13 | $971 |
| 99205 Office E&M - New | Office | 14 | 14 | $142.92 | $2,001 |
By year: 2022 $78K for 847 services; 2023 $79K for 988 services; 2024 $63K for 647 services.
Medicare prescription drug claims, 2024
In 2024, the drug Tilak K Mallik prescribed most often to Medicare patients was Synthroid (Levothyroxine Sodium), with 434 prescriptions and refills. In total Tilak K Mallik wrote 6,149 Medicare prescriptions that cost $2.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Synthroid Levothyroxine Sodium | 434 | 942 | 105 | $43K |
| Levothyroxine Sodium Generic | 293 | 768 | 88 | $1,901 |
| Ozempic Semaglutide | 290 | 464 | 81 | $450K |
| Metformin Hcl Generic | 269 | 760 | 89 | $1,586 |
| Rosuvastatin Calcium Generic | 255 | 704 | 79 | $2,153 |
| Jardiance Empagliflozin | 221 | 369 | 58 | $219K |
| Metformin Hcl Er Metformin Hcl | 159 | 426 | 58 | $1,590 |
| Glimepiride Generic | 136 | 364 | 44 | $1,028 |
| Atorvastatin Calcium Generic | 136 | 390 | 51 | $1,030 |
| Unithroid Levothyroxine Sodium | 132 | 364 | 43 | $18K |
| Trulicity Dulaglutide | 124 | 209 | 33 | $210K |
| Tresiba Flextouch U-100 Insulin Degludec | 122 | 260 | 34 | $69K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 116 | 260 | 39 | $13K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 113 | 243 | 39 | $13K |
| Mounjaro Tirzepatide | 111 | 161 | 31 | $174K |
Brand drugs: 3,196 claims; generic drugs: 2,488 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Tilak K Mallik $7,850 ($1,600 in general payments such as food, travel and fees and $6,250 for research) from 19 companies. The largest payer was Takeda Pharmaceuticals U.S.A., Inc. with $6,250.
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 10 | $6,250 |
| Novo Nordisk Inc NVO | 14 | $268 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 12 | $222 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 9 | $155 |
| Xeris Pharmaceuticals, Inc. | 7 | $151 |
| Abbvie Inc. ABBV | 8 | $141 |
| Medtronic, Inc. MDT | 6 | $123 |
| Ascendis Pharma Endocrinology Inc ASND | 3 | $76.41 |
| Lilly USA, LLC LLY | 3 | $69.67 |
| Amgen Inc. AMGN | 3 | $68.04 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.